Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 07 February 2013.
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: final appraisal determination document
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: consultee and commentator comments on the ACD
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Expert comments on the ACD
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Comments on the ACD received from the public through the NICE website
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: additional evidence
This page was last updated: 25 January 2013